Format

Send to

Choose Destination
Clin Chest Med. 2011 Dec;32(4):853-63. doi: 10.1016/j.ccm.2011.07.002. Epub 2011 Sep 28.

Current management of small cell lung cancer.

Author information

1
Stanford Cancer Institute, Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA. jwneal@stanford.edu

Abstract

Confined to one side of the chest, limited stage small cell lung cancer is treated with a combination of chemotherapy and radiotherapy, yet has a long-term survival rate of only 15%. Extensive stage disease has initial response rates to chemotherapy exceeding 70%. However, the disease almost invariably progresses and becomes fatal. Many recent clinical trials have failed to show superiority of newer chemotherapeutics or targeted therapies compared with the standard chemotherapy backbone of platinum plus etoposide. Numerous promising targeted therapies and other agents are still in development.

PMID:
22054891
DOI:
10.1016/j.ccm.2011.07.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center